Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction from a Secondary Database Analysis

    May 2026 in “ Dermatology and Therapy ”
    Samantha K. Kurosky, Ashley S. Cha-Silva, Jenny Austin … Benjamin Ungar
    Studysummary This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Updated Integrated Safety Analysis of Ritlecitinib Up to Five Years in Patients With Alopecia Areata From the Allegro Clinical Trial Program American Journal of Clinical Dermatology · 2025
    2. The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland Journal of Patient Experience · 2025
    3. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    4. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    5. British Association of Dermatologists Living Guideline for Managing People with Alopecia Areata 2024 British Journal of Dermatology · 2024
    6. Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe Dermatology and Therapy · 2024
    7. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    8. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    9. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    10. The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata Dermatology and Therapy · 2022
    11. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    12. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review Dermatology and Therapy · 2021
    13. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    14. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States Clinical Cosmetic and Investigational Dermatology · 2020
    15. Italian Guidelines in Diagnosis and Treatment of Alopecia Areata Giornale italiano di dermatologia e venereologia · 2019
    16. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    17. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014